Global Hormonal Contraceptive Market

Hormonal Contraceptive Comprehensive Study by Type (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Transdermal Patches), Formulations (Combined Method, Progestogen Method), End-users (Hospitals, Household, Clinics, Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), Hormones (Androgens, Estrogens, Progestogens, Gonadotropins, Antiandrogens, Others) Players and Region - Global Market Outlook to 2030

Hormonal Contraceptive Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.31%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hormonal Contraceptive
Hormonal contraceptives such as the pill, the patch, and the vaginal ring contain a small amount of man-made estrogen and progestin hormones. These hormones inhibit the body's natural cyclical hormones to prevent pregnancy. It stops the body from ovulating. It can also change the lining of the womb, which makes it unlikely the fertilized egg will be implanted. It is primarily used for the prevention of pregnancy. It can be also prescribed for the treatment of polycystic ovary syndrome, menstrual disorders such as dysmenorrhea and menorrhagia, and hirsutism.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR4.31%


The market for honeycomb sandwich materials is categorized into type and application sectors. In the upcoming years, the industry is expected to be dominated by the aluminum market category. This is brought on by a variety of factors, including as the growth of the auto industry, the manufacture of aircraft, and the increasing acceptance of lightweight and fuel-efficient cars. Weight also plays a big part in how effective an aircraft is in general. Due to its high mechanical qualities, aluminum honeycomb sandwich material offers significant potential in a variety of applications. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Hormonal Contraceptive market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Ansell (Australia), Bayer AG (Germany), Church & Dwight Co (United States), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Mylan N.V. (United States), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), The Female Health Company (United States) and Organon International (Netherlands) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Afaxys, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Hormonal Contraceptive market by Type (Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches) and Region.



On the basis of geography, the market of Hormonal Contraceptive has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Formulations, the sub-segment i.e. Combined Method will boost the Hormonal Contraceptive market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Hormonal Contraceptive market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Hormonal Contraceptive market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Hormones, the sub-segment i.e. Androgens will boost the Hormonal Contraceptive market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Awareness among People about Emergency Contraception and Increasing Adoption of Long-acting Contraceptive Methods

Market Growth Drivers:
Increased Use of Hormonal Contraceptives, Ease of Availability of the Contraceptives and Growing Number of Online Pharmacies

Challenges:
Stringent Government Rules and Regulations

Restraints:
Side Effects such as Headaches and Breakthrough Bleeding between Periods and Availability of the Alternative Products

Opportunities:
Growing Demand from Developing Countries, Growth in the Health Care Industry and Increasing Promotional Activities of the Companies

Market Leaders and their expansionary development strategies
In January 2020, Theramex has announced that it has entered into a definitive agreement to acquire further rights to Zoely, a patented oral contraceptive, from MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Theramex currently markets Zoely in eleven European countries, and this transaction will bring the total number of markets up to more than 50 on a global basis. MSD retains rights in the United States and Canada.
In July 2023, The U.S. Food and Drug Administration (FDA) approved Opill, a progestin-only (0.075-mg norgestrel) tablet. This progestin-only pill (POP) is approved without a prescription for adolescents and adults to prevent pregnancy.


Key Target Audience
Hormonal Contraceptives Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Oral Contraceptive Pills
  • Injectable Birth Control
  • Emergency Contraceptive Pills
  • Vaginal Rings
  • Transdermal Patches
By Formulations
  • Combined Method
  • Progestogen Method

By End-users
  • Hospitals
  • Household
  • Clinics
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Hormones
  • Androgens
  • Estrogens
  • Progestogens
  • Gonadotropins
  • Antiandrogens
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Use of Hormonal Contraceptives
      • 3.2.2. Ease of Availability of the Contraceptives
      • 3.2.3. Growing Number of Online Pharmacies
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness among People about Emergency Contraception
      • 3.4.2. Increasing Adoption of Long-acting Contraceptive Methods
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hormonal Contraceptive, by Type, Formulations, End-users, Distribution Channel, Hormones and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hormonal Contraceptive (Value)
      • 5.2.1. Global Hormonal Contraceptive by: Type (Value)
        • 5.2.1.1. Oral Contraceptive Pills
        • 5.2.1.2. Injectable Birth Control
        • 5.2.1.3. Emergency Contraceptive Pills
        • 5.2.1.4. Vaginal Rings
        • 5.2.1.5. Transdermal Patches
      • 5.2.2. Global Hormonal Contraceptive by: Formulations (Value)
        • 5.2.2.1. Combined Method
        • 5.2.2.2. Progestogen Method
      • 5.2.3. Global Hormonal Contraceptive by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Household
        • 5.2.3.3. Clinics
        • 5.2.3.4. Others
      • 5.2.4. Global Hormonal Contraceptive by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Online Pharmacies
        • 5.2.4.3. Retail Pharmacies
      • 5.2.5. Global Hormonal Contraceptive by: Hormones (Value)
        • 5.2.5.1. Androgens
        • 5.2.5.2. Estrogens
        • 5.2.5.3. Progestogens
        • 5.2.5.4. Gonadotropins
        • 5.2.5.5. Antiandrogens
        • 5.2.5.6. Others
      • 5.2.6. Global Hormonal Contraceptive Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Hormonal Contraceptive (Volume)
      • 5.3.1. Global Hormonal Contraceptive by: Type (Volume)
        • 5.3.1.1. Oral Contraceptive Pills
        • 5.3.1.2. Injectable Birth Control
        • 5.3.1.3. Emergency Contraceptive Pills
        • 5.3.1.4. Vaginal Rings
        • 5.3.1.5. Transdermal Patches
      • 5.3.2. Global Hormonal Contraceptive by: Formulations (Volume)
        • 5.3.2.1. Combined Method
        • 5.3.2.2. Progestogen Method
      • 5.3.3. Global Hormonal Contraceptive by: End-users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Household
        • 5.3.3.3. Clinics
        • 5.3.3.4. Others
      • 5.3.4. Global Hormonal Contraceptive by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Online Pharmacies
        • 5.3.4.3. Retail Pharmacies
      • 5.3.5. Global Hormonal Contraceptive by: Hormones (Volume)
        • 5.3.5.1. Androgens
        • 5.3.5.2. Estrogens
        • 5.3.5.3. Progestogens
        • 5.3.5.4. Gonadotropins
        • 5.3.5.5. Antiandrogens
        • 5.3.5.6. Others
      • 5.3.6. Global Hormonal Contraceptive Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Hormonal Contraceptive (Price)
      • 5.4.1. Global Hormonal Contraceptive by: Type (Price)
  • 6. Hormonal Contraceptive: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ansell (Australia)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Church & Dwight Co (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. The Female Health Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Organon International (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hormonal Contraceptive Sale, by Type, Formulations, End-users, Distribution Channel, Hormones and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hormonal Contraceptive (Value)
      • 7.2.1. Global Hormonal Contraceptive by: Type (Value)
        • 7.2.1.1. Oral Contraceptive Pills
        • 7.2.1.2. Injectable Birth Control
        • 7.2.1.3. Emergency Contraceptive Pills
        • 7.2.1.4. Vaginal Rings
        • 7.2.1.5. Transdermal Patches
      • 7.2.2. Global Hormonal Contraceptive by: Formulations (Value)
        • 7.2.2.1. Combined Method
        • 7.2.2.2. Progestogen Method
      • 7.2.3. Global Hormonal Contraceptive by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Household
        • 7.2.3.3. Clinics
        • 7.2.3.4. Others
      • 7.2.4. Global Hormonal Contraceptive by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Online Pharmacies
        • 7.2.4.3. Retail Pharmacies
      • 7.2.5. Global Hormonal Contraceptive by: Hormones (Value)
        • 7.2.5.1. Androgens
        • 7.2.5.2. Estrogens
        • 7.2.5.3. Progestogens
        • 7.2.5.4. Gonadotropins
        • 7.2.5.5. Antiandrogens
        • 7.2.5.6. Others
      • 7.2.6. Global Hormonal Contraceptive Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Hormonal Contraceptive (Volume)
      • 7.3.1. Global Hormonal Contraceptive by: Type (Volume)
        • 7.3.1.1. Oral Contraceptive Pills
        • 7.3.1.2. Injectable Birth Control
        • 7.3.1.3. Emergency Contraceptive Pills
        • 7.3.1.4. Vaginal Rings
        • 7.3.1.5. Transdermal Patches
      • 7.3.2. Global Hormonal Contraceptive by: Formulations (Volume)
        • 7.3.2.1. Combined Method
        • 7.3.2.2. Progestogen Method
      • 7.3.3. Global Hormonal Contraceptive by: End-users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Household
        • 7.3.3.3. Clinics
        • 7.3.3.4. Others
      • 7.3.4. Global Hormonal Contraceptive by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Online Pharmacies
        • 7.3.4.3. Retail Pharmacies
      • 7.3.5. Global Hormonal Contraceptive by: Hormones (Volume)
        • 7.3.5.1. Androgens
        • 7.3.5.2. Estrogens
        • 7.3.5.3. Progestogens
        • 7.3.5.4. Gonadotropins
        • 7.3.5.5. Antiandrogens
        • 7.3.5.6. Others
      • 7.3.6. Global Hormonal Contraceptive Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Hormonal Contraceptive (Price)
      • 7.4.1. Global Hormonal Contraceptive by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hormonal Contraceptive: by Type(USD Million)
  • Table 2. Hormonal Contraceptive Oral Contraceptive Pills , by Region USD Million (2018-2023)
  • Table 3. Hormonal Contraceptive Injectable Birth Control , by Region USD Million (2018-2023)
  • Table 4. Hormonal Contraceptive Emergency Contraceptive Pills , by Region USD Million (2018-2023)
  • Table 5. Hormonal Contraceptive Vaginal Rings , by Region USD Million (2018-2023)
  • Table 6. Hormonal Contraceptive Transdermal Patches , by Region USD Million (2018-2023)
  • Table 7. Hormonal Contraceptive: by Formulations(USD Million)
  • Table 8. Hormonal Contraceptive Combined Method , by Region USD Million (2018-2023)
  • Table 9. Hormonal Contraceptive Progestogen Method , by Region USD Million (2018-2023)
  • Table 10. Hormonal Contraceptive: by End-users(USD Million)
  • Table 11. Hormonal Contraceptive Hospitals , by Region USD Million (2018-2023)
  • Table 12. Hormonal Contraceptive Household , by Region USD Million (2018-2023)
  • Table 13. Hormonal Contraceptive Clinics , by Region USD Million (2018-2023)
  • Table 14. Hormonal Contraceptive Others , by Region USD Million (2018-2023)
  • Table 15. Hormonal Contraceptive: by Distribution Channel(USD Million)
  • Table 16. Hormonal Contraceptive Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 17. Hormonal Contraceptive Online Pharmacies , by Region USD Million (2018-2023)
  • Table 18. Hormonal Contraceptive Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 19. Hormonal Contraceptive: by Hormones(USD Million)
  • Table 20. Hormonal Contraceptive Androgens , by Region USD Million (2018-2023)
  • Table 21. Hormonal Contraceptive Estrogens , by Region USD Million (2018-2023)
  • Table 22. Hormonal Contraceptive Progestogens , by Region USD Million (2018-2023)
  • Table 23. Hormonal Contraceptive Gonadotropins , by Region USD Million (2018-2023)
  • Table 24. Hormonal Contraceptive Antiandrogens , by Region USD Million (2018-2023)
  • Table 25. Hormonal Contraceptive Others , by Region USD Million (2018-2023)
  • Table 26. South America Hormonal Contraceptive, by Country USD Million (2018-2023)
  • Table 27. South America Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 28. South America Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 29. South America Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 30. South America Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 31. South America Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 32. Brazil Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 33. Brazil Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 34. Brazil Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 35. Brazil Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 36. Brazil Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 37. Argentina Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 38. Argentina Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 39. Argentina Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 40. Argentina Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 41. Argentina Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 42. Rest of South America Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 43. Rest of South America Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 44. Rest of South America Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 45. Rest of South America Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 46. Rest of South America Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 47. Asia Pacific Hormonal Contraceptive, by Country USD Million (2018-2023)
  • Table 48. Asia Pacific Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 49. Asia Pacific Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 50. Asia Pacific Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 51. Asia Pacific Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 52. Asia Pacific Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 53. China Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 54. China Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 55. China Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 56. China Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 57. China Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 58. Japan Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 59. Japan Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 60. Japan Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 61. Japan Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 62. Japan Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 63. India Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 64. India Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 65. India Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 66. India Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 67. India Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 68. South Korea Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 69. South Korea Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 70. South Korea Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 71. South Korea Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 72. South Korea Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 73. Taiwan Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 74. Taiwan Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 75. Taiwan Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 76. Taiwan Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 77. Taiwan Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 78. Australia Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 79. Australia Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 80. Australia Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 81. Australia Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 82. Australia Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 88. Europe Hormonal Contraceptive, by Country USD Million (2018-2023)
  • Table 89. Europe Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 90. Europe Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 91. Europe Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 92. Europe Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 93. Europe Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 94. Germany Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 95. Germany Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 96. Germany Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 97. Germany Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 98. Germany Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 99. France Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 100. France Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 101. France Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 102. France Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 103. France Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 104. Italy Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 105. Italy Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 106. Italy Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 107. Italy Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 108. Italy Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 109. United Kingdom Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 110. United Kingdom Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 111. United Kingdom Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 112. United Kingdom Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 113. United Kingdom Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 114. Netherlands Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 115. Netherlands Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 116. Netherlands Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 117. Netherlands Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 118. Netherlands Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 119. Rest of Europe Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 120. Rest of Europe Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 121. Rest of Europe Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 122. Rest of Europe Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 123. Rest of Europe Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 124. MEA Hormonal Contraceptive, by Country USD Million (2018-2023)
  • Table 125. MEA Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 126. MEA Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 127. MEA Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 128. MEA Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 129. MEA Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 130. Middle East Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 131. Middle East Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 132. Middle East Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 133. Middle East Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 134. Middle East Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 135. Africa Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 136. Africa Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 137. Africa Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 138. Africa Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 139. Africa Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 140. North America Hormonal Contraceptive, by Country USD Million (2018-2023)
  • Table 141. North America Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 142. North America Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 143. North America Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 144. North America Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 145. North America Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 146. United States Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 147. United States Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 148. United States Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 149. United States Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 150. United States Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 151. Canada Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 152. Canada Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 153. Canada Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 154. Canada Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 155. Canada Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 156. Mexico Hormonal Contraceptive, by Type USD Million (2018-2023)
  • Table 157. Mexico Hormonal Contraceptive, by Formulations USD Million (2018-2023)
  • Table 158. Mexico Hormonal Contraceptive, by End-users USD Million (2018-2023)
  • Table 159. Mexico Hormonal Contraceptive, by Distribution Channel USD Million (2018-2023)
  • Table 160. Mexico Hormonal Contraceptive, by Hormones USD Million (2018-2023)
  • Table 161. Hormonal Contraceptive Sales: by Type(K Units)
  • Table 162. Hormonal Contraceptive Sales Oral Contraceptive Pills , by Region K Units (2018-2023)
  • Table 163. Hormonal Contraceptive Sales Injectable Birth Control , by Region K Units (2018-2023)
  • Table 164. Hormonal Contraceptive Sales Emergency Contraceptive Pills , by Region K Units (2018-2023)
  • Table 165. Hormonal Contraceptive Sales Vaginal Rings , by Region K Units (2018-2023)
  • Table 166. Hormonal Contraceptive Sales Transdermal Patches , by Region K Units (2018-2023)
  • Table 167. Hormonal Contraceptive Sales: by Formulations(K Units)
  • Table 168. Hormonal Contraceptive Sales Combined Method , by Region K Units (2018-2023)
  • Table 169. Hormonal Contraceptive Sales Progestogen Method , by Region K Units (2018-2023)
  • Table 170. Hormonal Contraceptive Sales: by End-users(K Units)
  • Table 171. Hormonal Contraceptive Sales Hospitals , by Region K Units (2018-2023)
  • Table 172. Hormonal Contraceptive Sales Household , by Region K Units (2018-2023)
  • Table 173. Hormonal Contraceptive Sales Clinics , by Region K Units (2018-2023)
  • Table 174. Hormonal Contraceptive Sales Others , by Region K Units (2018-2023)
  • Table 175. Hormonal Contraceptive Sales: by Distribution Channel(K Units)
  • Table 176. Hormonal Contraceptive Sales Hospital Pharmacies , by Region K Units (2018-2023)
  • Table 177. Hormonal Contraceptive Sales Online Pharmacies , by Region K Units (2018-2023)
  • Table 178. Hormonal Contraceptive Sales Retail Pharmacies , by Region K Units (2018-2023)
  • Table 179. Hormonal Contraceptive Sales: by Hormones(K Units)
  • Table 180. Hormonal Contraceptive Sales Androgens , by Region K Units (2018-2023)
  • Table 181. Hormonal Contraceptive Sales Estrogens , by Region K Units (2018-2023)
  • Table 182. Hormonal Contraceptive Sales Progestogens , by Region K Units (2018-2023)
  • Table 183. Hormonal Contraceptive Sales Gonadotropins , by Region K Units (2018-2023)
  • Table 184. Hormonal Contraceptive Sales Antiandrogens , by Region K Units (2018-2023)
  • Table 185. Hormonal Contraceptive Sales Others , by Region K Units (2018-2023)
  • Table 186. South America Hormonal Contraceptive Sales, by Country K Units (2018-2023)
  • Table 187. South America Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 188. South America Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 189. South America Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 190. South America Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 191. South America Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 192. Brazil Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 193. Brazil Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 194. Brazil Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 195. Brazil Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 196. Brazil Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 197. Argentina Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 198. Argentina Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 199. Argentina Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 200. Argentina Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 201. Argentina Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 202. Rest of South America Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 203. Rest of South America Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 204. Rest of South America Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 205. Rest of South America Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 206. Rest of South America Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 207. Asia Pacific Hormonal Contraceptive Sales, by Country K Units (2018-2023)
  • Table 208. Asia Pacific Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 209. Asia Pacific Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 210. Asia Pacific Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 211. Asia Pacific Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 212. Asia Pacific Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 213. China Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 214. China Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 215. China Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 216. China Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 217. China Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 218. Japan Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 219. Japan Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 220. Japan Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 221. Japan Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 222. Japan Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 223. India Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 224. India Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 225. India Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 226. India Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 227. India Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 228. South Korea Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 229. South Korea Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 230. South Korea Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 231. South Korea Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 232. South Korea Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 233. Taiwan Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 234. Taiwan Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 235. Taiwan Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 236. Taiwan Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 237. Taiwan Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 238. Australia Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 239. Australia Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 240. Australia Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 241. Australia Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 242. Australia Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 243. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 244. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 245. Rest of Asia-Pacific Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 246. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 247. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 248. Europe Hormonal Contraceptive Sales, by Country K Units (2018-2023)
  • Table 249. Europe Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 250. Europe Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 251. Europe Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 252. Europe Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 253. Europe Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 254. Germany Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 255. Germany Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 256. Germany Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 257. Germany Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 258. Germany Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 259. France Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 260. France Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 261. France Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 262. France Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 263. France Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 264. Italy Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 265. Italy Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 266. Italy Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 267. Italy Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 268. Italy Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 269. United Kingdom Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 270. United Kingdom Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 271. United Kingdom Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 272. United Kingdom Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 273. United Kingdom Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 274. Netherlands Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 275. Netherlands Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 276. Netherlands Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 277. Netherlands Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 278. Netherlands Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 279. Rest of Europe Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 280. Rest of Europe Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 281. Rest of Europe Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 282. Rest of Europe Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 283. Rest of Europe Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 284. MEA Hormonal Contraceptive Sales, by Country K Units (2018-2023)
  • Table 285. MEA Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 286. MEA Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 287. MEA Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 288. MEA Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 289. MEA Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 290. Middle East Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 291. Middle East Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 292. Middle East Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 293. Middle East Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 294. Middle East Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 295. Africa Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 296. Africa Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 297. Africa Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 298. Africa Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 299. Africa Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 300. North America Hormonal Contraceptive Sales, by Country K Units (2018-2023)
  • Table 301. North America Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 302. North America Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 303. North America Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 304. North America Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 305. North America Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 306. United States Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 307. United States Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 308. United States Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 309. United States Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 310. United States Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 311. Canada Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 312. Canada Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 313. Canada Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 314. Canada Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 315. Canada Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 316. Mexico Hormonal Contraceptive Sales, by Type K Units (2018-2023)
  • Table 317. Mexico Hormonal Contraceptive Sales, by Formulations K Units (2018-2023)
  • Table 318. Mexico Hormonal Contraceptive Sales, by End-users K Units (2018-2023)
  • Table 319. Mexico Hormonal Contraceptive Sales, by Distribution Channel K Units (2018-2023)
  • Table 320. Mexico Hormonal Contraceptive Sales, by Hormones K Units (2018-2023)
  • Table 321. Hormonal Contraceptive: by Type(USD/Units)
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Hormonal Contraceptive: by Type(USD Million)
  • Table 333. Hormonal Contraceptive Oral Contraceptive Pills , by Region USD Million (2025-2030)
  • Table 334. Hormonal Contraceptive Injectable Birth Control , by Region USD Million (2025-2030)
  • Table 335. Hormonal Contraceptive Emergency Contraceptive Pills , by Region USD Million (2025-2030)
  • Table 336. Hormonal Contraceptive Vaginal Rings , by Region USD Million (2025-2030)
  • Table 337. Hormonal Contraceptive Transdermal Patches , by Region USD Million (2025-2030)
  • Table 338. Hormonal Contraceptive: by Formulations(USD Million)
  • Table 339. Hormonal Contraceptive Combined Method , by Region USD Million (2025-2030)
  • Table 340. Hormonal Contraceptive Progestogen Method , by Region USD Million (2025-2030)
  • Table 341. Hormonal Contraceptive: by End-users(USD Million)
  • Table 342. Hormonal Contraceptive Hospitals , by Region USD Million (2025-2030)
  • Table 343. Hormonal Contraceptive Household , by Region USD Million (2025-2030)
  • Table 344. Hormonal Contraceptive Clinics , by Region USD Million (2025-2030)
  • Table 345. Hormonal Contraceptive Others , by Region USD Million (2025-2030)
  • Table 346. Hormonal Contraceptive: by Distribution Channel(USD Million)
  • Table 347. Hormonal Contraceptive Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 348. Hormonal Contraceptive Online Pharmacies , by Region USD Million (2025-2030)
  • Table 349. Hormonal Contraceptive Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 350. Hormonal Contraceptive: by Hormones(USD Million)
  • Table 351. Hormonal Contraceptive Androgens , by Region USD Million (2025-2030)
  • Table 352. Hormonal Contraceptive Estrogens , by Region USD Million (2025-2030)
  • Table 353. Hormonal Contraceptive Progestogens , by Region USD Million (2025-2030)
  • Table 354. Hormonal Contraceptive Gonadotropins , by Region USD Million (2025-2030)
  • Table 355. Hormonal Contraceptive Antiandrogens , by Region USD Million (2025-2030)
  • Table 356. Hormonal Contraceptive Others , by Region USD Million (2025-2030)
  • Table 357. South America Hormonal Contraceptive, by Country USD Million (2025-2030)
  • Table 358. South America Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 359. South America Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 360. South America Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 361. South America Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 362. South America Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 363. Brazil Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 364. Brazil Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 365. Brazil Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 366. Brazil Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 367. Brazil Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 368. Argentina Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 369. Argentina Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 370. Argentina Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 371. Argentina Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 372. Argentina Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 373. Rest of South America Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 374. Rest of South America Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 375. Rest of South America Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 376. Rest of South America Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 377. Rest of South America Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 378. Asia Pacific Hormonal Contraceptive, by Country USD Million (2025-2030)
  • Table 379. Asia Pacific Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 380. Asia Pacific Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 381. Asia Pacific Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 382. Asia Pacific Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 383. Asia Pacific Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 384. China Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 385. China Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 386. China Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 387. China Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 388. China Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 389. Japan Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 390. Japan Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 391. Japan Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 392. Japan Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 393. Japan Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 394. India Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 395. India Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 396. India Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 397. India Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 398. India Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 399. South Korea Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 400. South Korea Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 401. South Korea Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 402. South Korea Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 403. South Korea Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 404. Taiwan Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 405. Taiwan Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 406. Taiwan Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 407. Taiwan Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 408. Taiwan Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 409. Australia Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 410. Australia Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 411. Australia Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 412. Australia Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 413. Australia Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 414. Rest of Asia-Pacific Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 415. Rest of Asia-Pacific Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 416. Rest of Asia-Pacific Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 417. Rest of Asia-Pacific Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 418. Rest of Asia-Pacific Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 419. Europe Hormonal Contraceptive, by Country USD Million (2025-2030)
  • Table 420. Europe Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 421. Europe Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 422. Europe Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 423. Europe Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 424. Europe Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 425. Germany Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 426. Germany Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 427. Germany Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 428. Germany Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 429. Germany Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 430. France Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 431. France Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 432. France Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 433. France Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 434. France Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 435. Italy Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 436. Italy Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 437. Italy Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 438. Italy Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 439. Italy Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 440. United Kingdom Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 441. United Kingdom Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 442. United Kingdom Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 443. United Kingdom Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 444. United Kingdom Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 445. Netherlands Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 446. Netherlands Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 447. Netherlands Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 448. Netherlands Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 449. Netherlands Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 450. Rest of Europe Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 451. Rest of Europe Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 452. Rest of Europe Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 453. Rest of Europe Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 454. Rest of Europe Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 455. MEA Hormonal Contraceptive, by Country USD Million (2025-2030)
  • Table 456. MEA Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 457. MEA Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 458. MEA Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 459. MEA Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 460. MEA Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 461. Middle East Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 462. Middle East Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 463. Middle East Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 464. Middle East Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 465. Middle East Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 466. Africa Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 467. Africa Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 468. Africa Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 469. Africa Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 470. Africa Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 471. North America Hormonal Contraceptive, by Country USD Million (2025-2030)
  • Table 472. North America Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 473. North America Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 474. North America Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 475. North America Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 476. North America Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 477. United States Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 478. United States Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 479. United States Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 480. United States Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 481. United States Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 482. Canada Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 483. Canada Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 484. Canada Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 485. Canada Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 486. Canada Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 487. Mexico Hormonal Contraceptive, by Type USD Million (2025-2030)
  • Table 488. Mexico Hormonal Contraceptive, by Formulations USD Million (2025-2030)
  • Table 489. Mexico Hormonal Contraceptive, by End-users USD Million (2025-2030)
  • Table 490. Mexico Hormonal Contraceptive, by Distribution Channel USD Million (2025-2030)
  • Table 491. Mexico Hormonal Contraceptive, by Hormones USD Million (2025-2030)
  • Table 492. Hormonal Contraceptive Sales: by Type(K Units)
  • Table 493. Hormonal Contraceptive Sales Oral Contraceptive Pills , by Region K Units (2025-2030)
  • Table 494. Hormonal Contraceptive Sales Injectable Birth Control , by Region K Units (2025-2030)
  • Table 495. Hormonal Contraceptive Sales Emergency Contraceptive Pills , by Region K Units (2025-2030)
  • Table 496. Hormonal Contraceptive Sales Vaginal Rings , by Region K Units (2025-2030)
  • Table 497. Hormonal Contraceptive Sales Transdermal Patches , by Region K Units (2025-2030)
  • Table 498. Hormonal Contraceptive Sales: by Formulations(K Units)
  • Table 499. Hormonal Contraceptive Sales Combined Method , by Region K Units (2025-2030)
  • Table 500. Hormonal Contraceptive Sales Progestogen Method , by Region K Units (2025-2030)
  • Table 501. Hormonal Contraceptive Sales: by End-users(K Units)
  • Table 502. Hormonal Contraceptive Sales Hospitals , by Region K Units (2025-2030)
  • Table 503. Hormonal Contraceptive Sales Household , by Region K Units (2025-2030)
  • Table 504. Hormonal Contraceptive Sales Clinics , by Region K Units (2025-2030)
  • Table 505. Hormonal Contraceptive Sales Others , by Region K Units (2025-2030)
  • Table 506. Hormonal Contraceptive Sales: by Distribution Channel(K Units)
  • Table 507. Hormonal Contraceptive Sales Hospital Pharmacies , by Region K Units (2025-2030)
  • Table 508. Hormonal Contraceptive Sales Online Pharmacies , by Region K Units (2025-2030)
  • Table 509. Hormonal Contraceptive Sales Retail Pharmacies , by Region K Units (2025-2030)
  • Table 510. Hormonal Contraceptive Sales: by Hormones(K Units)
  • Table 511. Hormonal Contraceptive Sales Androgens , by Region K Units (2025-2030)
  • Table 512. Hormonal Contraceptive Sales Estrogens , by Region K Units (2025-2030)
  • Table 513. Hormonal Contraceptive Sales Progestogens , by Region K Units (2025-2030)
  • Table 514. Hormonal Contraceptive Sales Gonadotropins , by Region K Units (2025-2030)
  • Table 515. Hormonal Contraceptive Sales Antiandrogens , by Region K Units (2025-2030)
  • Table 516. Hormonal Contraceptive Sales Others , by Region K Units (2025-2030)
  • Table 517. South America Hormonal Contraceptive Sales, by Country K Units (2025-2030)
  • Table 518. South America Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 519. South America Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 520. South America Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 521. South America Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 522. South America Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 523. Brazil Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 524. Brazil Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 525. Brazil Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 526. Brazil Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 527. Brazil Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 528. Argentina Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 529. Argentina Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 530. Argentina Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 531. Argentina Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 532. Argentina Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 533. Rest of South America Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 534. Rest of South America Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 535. Rest of South America Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 536. Rest of South America Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 537. Rest of South America Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 538. Asia Pacific Hormonal Contraceptive Sales, by Country K Units (2025-2030)
  • Table 539. Asia Pacific Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 540. Asia Pacific Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 541. Asia Pacific Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 542. Asia Pacific Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 543. Asia Pacific Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 544. China Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 545. China Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 546. China Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 547. China Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 548. China Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 549. Japan Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 550. Japan Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 551. Japan Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 552. Japan Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 553. Japan Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 554. India Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 555. India Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 556. India Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 557. India Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 558. India Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 559. South Korea Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 560. South Korea Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 561. South Korea Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 562. South Korea Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 563. South Korea Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 564. Taiwan Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 565. Taiwan Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 566. Taiwan Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 567. Taiwan Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 568. Taiwan Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 569. Australia Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 570. Australia Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 571. Australia Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 572. Australia Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 573. Australia Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 574. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 575. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 576. Rest of Asia-Pacific Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 577. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 578. Rest of Asia-Pacific Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 579. Europe Hormonal Contraceptive Sales, by Country K Units (2025-2030)
  • Table 580. Europe Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 581. Europe Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 582. Europe Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 583. Europe Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 584. Europe Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 585. Germany Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 586. Germany Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 587. Germany Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 588. Germany Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 589. Germany Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 590. France Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 591. France Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 592. France Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 593. France Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 594. France Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 595. Italy Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 596. Italy Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 597. Italy Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 598. Italy Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 599. Italy Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 600. United Kingdom Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 601. United Kingdom Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 602. United Kingdom Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 603. United Kingdom Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 604. United Kingdom Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 605. Netherlands Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 606. Netherlands Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 607. Netherlands Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 608. Netherlands Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 609. Netherlands Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 610. Rest of Europe Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 611. Rest of Europe Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 612. Rest of Europe Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 613. Rest of Europe Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 614. Rest of Europe Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 615. MEA Hormonal Contraceptive Sales, by Country K Units (2025-2030)
  • Table 616. MEA Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 617. MEA Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 618. MEA Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 619. MEA Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 620. MEA Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 621. Middle East Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 622. Middle East Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 623. Middle East Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 624. Middle East Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 625. Middle East Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 626. Africa Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 627. Africa Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 628. Africa Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 629. Africa Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 630. Africa Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 631. North America Hormonal Contraceptive Sales, by Country K Units (2025-2030)
  • Table 632. North America Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 633. North America Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 634. North America Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 635. North America Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 636. North America Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 637. United States Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 638. United States Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 639. United States Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 640. United States Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 641. United States Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 642. Canada Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 643. Canada Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 644. Canada Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 645. Canada Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 646. Canada Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 647. Mexico Hormonal Contraceptive Sales, by Type K Units (2025-2030)
  • Table 648. Mexico Hormonal Contraceptive Sales, by Formulations K Units (2025-2030)
  • Table 649. Mexico Hormonal Contraceptive Sales, by End-users K Units (2025-2030)
  • Table 650. Mexico Hormonal Contraceptive Sales, by Distribution Channel K Units (2025-2030)
  • Table 651. Mexico Hormonal Contraceptive Sales, by Hormones K Units (2025-2030)
  • Table 652. Hormonal Contraceptive: by Type(USD/Units)
  • Table 653. Research Programs/Design for This Report
  • Table 654. Key Data Information from Secondary Sources
  • Table 655. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hormonal Contraceptive: by Type USD Million (2018-2023)
  • Figure 5. Global Hormonal Contraceptive: by Formulations USD Million (2018-2023)
  • Figure 6. Global Hormonal Contraceptive: by End-users USD Million (2018-2023)
  • Figure 7. Global Hormonal Contraceptive: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Hormonal Contraceptive: by Hormones USD Million (2018-2023)
  • Figure 9. South America Hormonal Contraceptive Share (%), by Country
  • Figure 10. Asia Pacific Hormonal Contraceptive Share (%), by Country
  • Figure 11. Europe Hormonal Contraceptive Share (%), by Country
  • Figure 12. MEA Hormonal Contraceptive Share (%), by Country
  • Figure 13. North America Hormonal Contraceptive Share (%), by Country
  • Figure 14. Global Hormonal Contraceptive: by Type K Units (2018-2023)
  • Figure 15. Global Hormonal Contraceptive: by Formulations K Units (2018-2023)
  • Figure 16. Global Hormonal Contraceptive: by End-users K Units (2018-2023)
  • Figure 17. Global Hormonal Contraceptive: by Distribution Channel K Units (2018-2023)
  • Figure 18. Global Hormonal Contraceptive: by Hormones K Units (2018-2023)
  • Figure 19. South America Hormonal Contraceptive Share (%), by Country
  • Figure 20. Asia Pacific Hormonal Contraceptive Share (%), by Country
  • Figure 21. Europe Hormonal Contraceptive Share (%), by Country
  • Figure 22. MEA Hormonal Contraceptive Share (%), by Country
  • Figure 23. North America Hormonal Contraceptive Share (%), by Country
  • Figure 24. Global Hormonal Contraceptive: by Type USD/Units (2018-2023)
  • Figure 25. Global Hormonal Contraceptive share by Players 2023 (%)
  • Figure 26. Global Hormonal Contraceptive share by Players (Top 3) 2023(%)
  • Figure 27. Global Hormonal Contraceptive share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Ansell (Australia) Revenue, Net Income and Gross profit
  • Figure 30. Ansell (Australia) Revenue: by Geography 2023
  • Figure 31. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 33. Church & Dwight Co (United States) Revenue, Net Income and Gross profit
  • Figure 34. Church & Dwight Co (United States) Revenue: by Geography 2023
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 37. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 41. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 44. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 45. The Female Health Company (United States) Revenue, Net Income and Gross profit
  • Figure 46. The Female Health Company (United States) Revenue: by Geography 2023
  • Figure 47. Organon International (Netherlands) Revenue, Net Income and Gross profit
  • Figure 48. Organon International (Netherlands) Revenue: by Geography 2023
  • Figure 49. Global Hormonal Contraceptive: by Type USD Million (2025-2030)
  • Figure 50. Global Hormonal Contraceptive: by Formulations USD Million (2025-2030)
  • Figure 51. Global Hormonal Contraceptive: by End-users USD Million (2025-2030)
  • Figure 52. Global Hormonal Contraceptive: by Distribution Channel USD Million (2025-2030)
  • Figure 53. Global Hormonal Contraceptive: by Hormones USD Million (2025-2030)
  • Figure 54. South America Hormonal Contraceptive Share (%), by Country
  • Figure 55. Asia Pacific Hormonal Contraceptive Share (%), by Country
  • Figure 56. Europe Hormonal Contraceptive Share (%), by Country
  • Figure 57. MEA Hormonal Contraceptive Share (%), by Country
  • Figure 58. North America Hormonal Contraceptive Share (%), by Country
  • Figure 59. Global Hormonal Contraceptive: by Type K Units (2025-2030)
  • Figure 60. Global Hormonal Contraceptive: by Formulations K Units (2025-2030)
  • Figure 61. Global Hormonal Contraceptive: by End-users K Units (2025-2030)
  • Figure 62. Global Hormonal Contraceptive: by Distribution Channel K Units (2025-2030)
  • Figure 63. Global Hormonal Contraceptive: by Hormones K Units (2025-2030)
  • Figure 64. South America Hormonal Contraceptive Share (%), by Country
  • Figure 65. Asia Pacific Hormonal Contraceptive Share (%), by Country
  • Figure 66. Europe Hormonal Contraceptive Share (%), by Country
  • Figure 67. MEA Hormonal Contraceptive Share (%), by Country
  • Figure 68. North America Hormonal Contraceptive Share (%), by Country
  • Figure 69. Global Hormonal Contraceptive: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Ansell (Australia)
  • Bayer AG (Germany)
  • Church & Dwight Co (United States)
  • Johnson & Johnson (United States)
  • Merck & Co., Inc. (United States)
  • Mylan N.V. (United States)
  • Pfizer Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • The Female Health Company (United States)
  • Organon International (Netherlands)
Additional players considered in the study are as follows:
Afaxys, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 240 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hormonal Contraceptive Market Quantitative research analysis
Global Hormonal Contraceptive Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Ansell (Australia), Bayer AG (Germany), Church & Dwight Co (United States), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Mylan N.V. (United States), Pfizer Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), The Female Health Company (United States) and Organon International (Netherlands) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Awareness among People about Emergency Contraception " is seen as one of major influencing trends for Hormonal Contraceptive Market during projected period 2023-2030.
The Hormonal Contraceptive market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hormonal Contraceptive Market Report?

Have a Query? Click Here

Other Related Reports

Lectins Comprehensive Study by Type (Above 90%, Above 95%, Above 99%, Others), Application (Bioscience Research Institutions, Biopharmaceutical Companies, Hospitals, Others), End-Use Industry (Health...
$ 3350
Viral Molecular Diagnostics Comprehensive Study by Type (Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)), Application (Infectious Dis...
$ 3750
Simple Island Dressings Comprehensive Study by Type (Traditional Wound Dressings, Advanced Wound Dressings), Application (Wet Wound, Dry Wound), Distribution Channel (Online, Offline), Size (2"x2" (...
$ 3450
Teicoplanin Comprehensive Study by Type (200 mg, 400 mg), Application (Bone and Joint Infection, Severe Skin and Soft Tissue Infection, Bacteraemia, Others), End-User (Adults, Children) Players and R...
$ 3500
Protein A Resin Comprehensive Study by Type (Natural Protein A, Recombinant Protein A), Application (Immunoprecipitation, Antibody Purification), Matrix (Glass or Silica Gel-based Matrix, Agarose-bas...
$ 3450
Sage Herbs Comprehensive Study by Application (Food and Beverage, Dietary Supplements, Personal Care and Cosmetics, Others), Category (Organic Sage Herb, Conventional Sage Herb), Form (Powder Form, L...
$ 3800